The objective was to investigate whether myocardial adenosine triphosphate-sensitive K + (K ATP ) channels open during the first 10 min of regional ischaemia in Langendorff-perfused rat hearts. Changes in monophasic action potentials and arrhythmias were studied during myocardial ischaemia in both the presence and absence of pharmacological K ATP modulation. Ligation of the left main coronary artery for 10 min did not shorten the action potential duration (APD). The APD 50 and APD 80 (15.5 ± 1.0 and 38.1 ± 2.3 ms, respectively [mean ± S.E., n = 15 hearts], immediately prior to ligation) increased transiently during the first 4 min of ligation (by 160 and 79 % respectively, P < 0.05), before returning to pre-ligation values, but without a significant below-baseline-shortening. The cardiac electrogram showed no accompanying ventricular tachyarrhythmia (VT). These results raised the possibility that the myocardial K ATP channels had not opened during the ligation. The K ATP opener Ro 31-6930 (0.5 and 5 µM) shortened the APD 50 and APD 80 during coronary ligation, to significantly below both their control and pre-occlusion values (P < 0.05), and caused a concentration-dependent increase in both the incidence and duration of VT during the ligation. Ro 31-6930 at 5 µM also shortened APD 50 and APD 80 even before ligation (by 50 and 62 % respectively, P < 0.05), and abolished the normal APD-lengthening seen during ischaemia. The K ATP blocker glibenclamide (1 µM) abolished both the APD-shortening and pro-arrhythmic effects of the K ATP opener, both before and during coronary ligation, yet when delivered on its own, at the same concentration which abolished the effects of K ATP activation, it had no significant effect on the APD changes seen during the coronary ligation alone. These results suggest that, in Langendorff-perfused rat hearts in the absence of drugs, K ATP channels do not open during early myocardial ischaemia.
Introduction
In cardiac myocytes the normal intracellular ATP concentration keeps adenosine triphosphate-sensitive K + (K ATP ) channels in a closed state, but ATP removal can open them (25) . Under certain conditions, this increases cellular K + efflux, with a profound alteration of normal cardiac electrical activity, such as shortening of the action potential duration (APD) (39). Shortening of the action potential caused by the K ATP current (I KATP ) may protect the ischaemic myocardium by reducing intracellular Ca 2+ overload and by conserving intracellular stores of ATP. However, by concomitantly shortening the refractory period, any APD reduction would favour reentrant arrhythmias (6, 15) . It should be noted that the newly recognised mitochondrial K ATP channel, mitoK ATP (which may open more readily than sarcolemmal K ATP ) may also be involved in myocardial protection, but this would not be expected to be reflected by changes in the APD (11) . For reviews on the various electrical consequences of cardiac sarcolemmal K ATP channel activation, see (2, 24, 39) .
Several lines of evidence indicate that K ATP channels can open within the first 5 to 10 min of acute myocardial ischaemia, i.e. before necrosis would be expected, but when lethal arrhythmias may occur. Thus, APD shortens within about 3 min of ischaemia onset in several species, and is sensitive to K ATP blockers in the intact hearts of dogs and rabbits (30) . Additionally, K ATP openers have been reported to cause, and K ATP blockers to prevent, various ventricular arrhythmias during acute myocardial ischaemia in several species, including the rat (9, 16) .
However, ionic currents additional to I KATP are known to participate in APD-shortening during early ischaemia (4) , and, there is evidence to suggest that K ATP activation may not be the main cause of such APD-shortening. For example, the reversal of APD-shortening in rabbits by the K ATP blocker glibenclamide occurs well after 10 min of ischaemia or hypoxia have elapsed (1, 29) , even though APD-shortening in this species occurs within 3 min of ischaemia. Moreover, only partial reversal by glibenclamide of the APD-shortening effects of ischaemia or hypoxia have been observed (30) . Indeed, K ATP channels may not open at all under certain conditions. The intracellular ATP concentration remained in the millimolar range (perhaps as high as 10 mM) for the first 10 min in some studies (18) , yet half maximal inhibition of K ATP channels in excised membrane patches is known to occur at 17-25 µM (17) , and so the possibility remains that significant K ATP activation may not occur during early ischaemia, even when taking into account the limitations involved in comparing data obtained using different experimental techniques (24) .
The rat has been used extensively to investigate the effects of pharmacological K ATP modulators on arrhythmogenesis. In this species, an accumulation of K + in the extracellular space has been detected after only 15 s of ischaemia, with [K + ] o reaching 9 mM after 5 min. However, glibenclamide only partially altered this accumulation (with [K + ] o still reaching 8 mM after 5 min) and exerted even less of an effect up to 25 min beyond this time (38). This suggested only a limited involvement of K ATP channels during early ischaemia in this species. Moreover, the APD has been shown to increase markedly during the first few minutes of ischaemia in the rat (26) (27) (28) 40) , i.e. at a time when any K ATP activation might have been expected to shorten APD. Furthermore, the APD was shown not to shorten at all during global ischaemia but to exhibit transient lengthening during the first 5 min, followed by a second increase during the following 15 min (26) . An activation of only 1 % of the available K ATP conductance should be sufficient to shorten APD by approximately 50 % (24) . We therefore hypothesised that K ATP channels might not open during early ischaemia in this species. Ischaemic APDlengthening (or a lack of APD-shortening) per se does not preclude concurrent K ATP activation, and so data on the sensitivity of such changes to K ATP blockers is required. There are currently no reports of investigations into the effects of K ATP blockers on APD during ischaemia in intact rat hearts.
The aim of the present study, therefore, was to investigate whether K ATP channels open during the first 10 min of myocardial ischaemia in Langendorff-perfused rat hearts, by assessing the sensitivity to pharmacologic K ATP modulation, of changes in action potentials and arrhythmias during regional ischaemia in these intact hearts.
Methods

Isolation and perfusion of rat hearts in vitro
The investigation conforms with the Guidance on the Operation of the Animals (Scientific Procedures) Act 1986. In accordance with Schedule 1, male Sprague Dawley rats (350-650 g) were killed by concussion, followed by exsanguination. The heart was surgically exposed and a silk suture (Type W593 Mersilk, Ethicon) was placed beneath the left main coronary artery. The aorta was then cannulated and the heart was rapidly excised and perfused in Langendorff mode at 35-37 °C (inside a water-heated covered glass chamber) with a physiological salt solution containing (mM): NaCl (136.9), glucose (11.1), MgCl 2 (1.0), NaH 2 PO 4 (0.3), NaHCO 3 (11.9), CaCl 2 (0.9) and KCl (5.0), pH 7.4. This solution was bubbled with 95 % O 2 plus 5 % CO 2 and pre-filtered using a 5 µm filter (Isopore SM, Millipore). The duration between concussion and exsanguination, and the start of Langendorff perfusion, was approximately 2-3 min.
Drugs
A stock solution of the K ATP opener Ro 31-6930 (Roche Research Centre) was dissolved in H 2 O, and was freshly prepared before each experiment. A stock solution of the K ATP blocker glibenclamide (Sigma) dissolved in dimethyl sulphoxide was prepared weekly and stored at 4 °C. These drugs were added to the physiological salt solution when required, prior to perfusing the hearts. Final concentrations of Ro 31-6930 were 50 nM -10 µM. Glibenclamide was used at 1 µM, with 0.002 % dimethyl sulphoxide in the final perfusate.
Electrical recording techniques
The cardiac electrogram (CEG) was recorded continuously using stainless steel wires inserted into the ventricular apex and the right atrium, respectively. Arrhythmias were monitored on a scroll-type storage oscilloscope (Cardiostore SEM 431, SE Labs), and categorised using the guidelines of the Lambeth Conventions (34) . Ventricular tachycardia and ventricular fibrillation were combined as ventricular tachyarrhythmia (VT). The heart rate was calculated from the CEG each minute, by measuring the number of QRS complexes which occurred during a 20 s interval. Action potentials were recorded, in separate groups of hearts, from the left ventricular epicardial wall, 4 mm distal to the coronary ligature, using a custom made suction electrode (internal diameter 1 mm, external diameter 1.3 mm), evacuated to 200 mm Hg below atmospheric pressure. Voltage signals were low-pass filtered at 5 kHz, digitised and stored on the magnetic disc of a scrolltype oscilloscope (Windograph, Gould).
Experimental protocols
Hearts were allowed to stabilise for 10 min by perfusing with the physiological salt solution. Recording of either the CEG or epicardial action potentials was then started. Perfusion fluid was switched to one containing drugs, if required, and baseline recordings continued for another 15 min. The coronary ligature was then closed around the left main coronary artery. Electrical recordings were continued throughout a 10 min period of ligation. This interval was chosen since it is substantially longer than that reported to be required for ischaemic-K ATP opening in many animal species, and would therefore aid comparison with those studies, and yet it would not be sufficiently long to cause myocardial necrosis. Coronary flow rate was measured by timed collection of coronary effluent. At the end of each experiment, the zone of non-perfused muscle was delineated using the technique of reverse staining, with Patent Blue V 1240 (at 4 g·l -1 ). This produced a distinct zone of dye-stained (non-perfused) muscle (risk zone), which invariably extended over approximately 50 % of the total ventricular surface, demonstrating the success of the coronary artery occlusion, and confirming the limited involvement of coronary collaterals in this species. Dye-stained and non-stained ventricular muscle masses were separated with scissors, blotted dry and weighed. In a separate group of 10 hearts, the suction electrode was replaced by a thermistor probe (Wayne Kerr), to measure the epicardial temperature in the ischaemic zone prior to and during coronary ligation.
Data analysis and statistics
APD measurements were excluded if the suction electrode was found to have not been located centrally in the non-perfused area of muscle. All values were expressed as means±standard error (S.E.). Incidences of arrhythmias were compared using a 2 test (with Yate's Correction). All data on arrhythmia duration, coronary flow rate and APD were subjected to a variance ratio test. Data were then compared using either a Student's t test or a Mann Whitney test (for non-parametric analysis), as appropriate. P < 0.05 was considered significant.
Results
Acute left ventricular regional ischaemia did not cause arrhythmias in isolated rat hearts
Ligation of the left main coronary artery for 10 min was not accompanied by any episode of VT in Langendorff-perfused rat hearts (n = 10), despite producing a distinct zone of nonperfused muscle in each heart. The incidence of VT was zero during the 10 min period prior to coronary occlusion. Occlusion abruptly reduced the total coronary flow rate from 10.6 ± 0.7 to 6.7 ± 0.6 ml · min -1 · g -1 ventricular weight (P < 0.05, n = 10, perfusion pressure = 100 cm H 2 0). The mean wet weight of the muscular zone at risk of ischaemia, as revealed by staining, was 0.67 ± 0.03 g, or 52 % of the total ventricular weight (n = 10). The heart rate was 237 ± 14 beats · min -1 1 min before coronary occlusion. During occlusion, the heart rate fell progressively, and to significantly below the pre-occlusion value only after 10 min, to 197 ± 18 beats · min -1 (P < 0.05).
The action potential duration did not shorten during coronary artery occlusion
Representative action potentials recorded from the left ventricular epicardium are shown in Fig. 1 , with the typical action potential configuration (short duration) seen prior to ischaemia in Fig. 1a . The time course of changes in left ventricular action potentials recorded during the 10 min period of coronary occlusion from the area at risk of ischaemia can be seen from the recordings in Fig. 1c . The APD at both 50 and 80 % repolarisation (APD 50 and APD 80 , respectively) was measured at a high time resolution (e.g. Fig. 1b) , and the mean time course of these changes was plotted graphically, as shown in the "control" curves of Fig. 2 . Neither APD 50 , nor APD 80 shortened during occlusion. Rather, there was a transient (3-4 min) increase in left ventricular APD at both measured levels of repolarisation, followed by a return to the pre-occlusion state in the last 4 or 5 min of occlusion, with no sign of a significant below-baseline-shortening of APD. Immediately prior to the occlusion, APD 50 and APD 80 values were 15.5 ± 1.0 and 38.1 ± 2.3 ms, respectively (n = 15 hearts). After only 1 min of occlusion, these had increased significantly, by 160 and 79 %, respectively (P < 0.05, n = 15), before returning to the pre-ischaemic state. The APD increase was not associated with any change in epicardial surface temperature. Prior to ischaemia, this was 37.3 ± 0.2 °C, and was not significantly different at the end of the period of ischaemia, at 36.6 ± 0.2 °C (n = 10). Action potential amplitude and duration were measured during prolonged perfusion in the absence of coronary artery occlusion in other hearts. At the start of the experiment, APD 80 and action potential amplitude were 37.6 ± 3.3 ms and 12.3 ± 1.8 mV, respectively. After 45 min of continuous perfusion, these values were not significantly different, at 34.1 ± 3.6 ms and 9.6 ± 2.1 mV, respectively. This demonstrates the substantial stability of the recordings, despite the application of prolonged suction.
A K ATP blocker did not alter action potentials during a 10 min coronary occlusion
The K ATP blocker glibenclamide at a concentration of 1 µM would be expected to have blocked open cardiac K ATP channels, but it had no effect on the APD changes caused by 10 min of coronary occlusion. This lack of effect of glibenclamide on both APD 50 and APD 80 is shown in Fig. 2 . The control and drug-treatment experiments were performed contemporaneously. There was no significant difference in the APD 50 or APD 80 values between these two groups at any time point during occlusion. Glibenclamide exerted a vasoconstrictor action in preliminary experiments, so perfusion pressure was raised to 133 cm H 2 0 for recording action potentials in glibenclamide-treated hearts, but kept at 100 cm H 2 0 in control hearts. This equalised coronary flow rates in the two groups, so that any effects of glibenclamide on APD were unlikely to have been obscured by its vasoconstrictor action.
A K ATP opener caused VT during the coronary occlusion
The K ATP opener Ro 31-6930 caused VT to occur during 10 min of coronary artery occlusion, and its incidence and duration were increased in a concentration-dependent manner by this drug. This can be seen in Fig. 3 , which shows the effects 2 Time course of APD changes during coronary occlusion, and lack of effect of a K ATP blocker. Following a 5 min period of baseline recording, the left main coronary artery was occluded at time zero (indicated by vertical arrow), and recordings were taken continuously for a further 10 min. Values (APD 50 and APD 80 ) are means (with error bars denoting S.E.); n = 15 hearts (6-15 action potentials) in both control and glibenclamide-treated groups. *denotes a significant difference (P < 0.05) from control values at each time point prior to and during coronary occlusion.
of Ro 31-6930 between 0.5 and 10 µM. In each case, Ro 31-6930 was introduced into the perfusate 15 min before the occlusion. VT only occurred to a significant extent (compared to controls) with high concentrations of Ro 31-6930, i.e. 5 or 10 µM (Fig. 3) . With Ro 31-6930 at 5 µM, no VT was observed prior to coronary occlusion, but a significant proportion of hearts displayed VT after only 4 min of the occlusion. However, at 10 µM, Ro 31-6930 caused significant VT even prior to coronary occlusion, with all hearts displaying continuous VT within 3 min of the occlusion. In preliminary experiments, Ro 31-6930 exerted a potent vasodilator action, even at 0.05 µM. This effect was maximal at 0.5 µM, causing an increase in the total coronary flow rate from 10.6 ± 0.7 to 14.5 ± 1.0 ml · min -1 ·g -1 ventricular weight (P < 0.05, n = 10). The perfusion pressure was therefore lowered to 66 cm H 2 0 when recording the CEG from hearts treated with the K ATP opener. This equalised the coronary flow rates between the control group and all the drug-treated groups. The effects of the K ATP opener on APD were unlikely therefore to have been obscured by its vasodilator action. The heart rate in groups treated with Ro 31-6930 at 0.5 and 5 µM was 225 ± 20 and 246 ± 16 beats · min -1 , respectively, 1 min before coronary occlusion. The heart rate did not differ significantly in either group, from that of the control group at any time point prior to or during the occlusion.
Pro-arrhythmic effects of the K ATP opener were glibenclamide-sensitive Glibenclamide, at the low concentration of 1 µM abolished the pro-arrhythmic effects of Ro 31-6930 at each concentration tested. This effect of glibenclamide is clearly illustrated in Fig. 3 , which shows both the incidence and duration of VT during ischaemia in groups of hearts perfused with various combinations of Ro 31-6930 and glibenclamide. Glibenclamide on its own (denoted in the histograms by 0 µM Ro 31-6930 in combination with 1 µM glibenclamide) did not cause VT to a significant extent (compared to controls) either before or during coronary occlusion, but prevented the pro-arrhythmic effects of Ro 31-6930 both before and during the period of coronary occlusion, even when in combination with Ro 31-6930 at the high concentration of 10 µM. The heart rate in those hearts treated with glibenclamide alone was 221 ± 13 beats · min -1 prior to coronary occlusion, and did not differ significantly from that of the control group at any time point prior to or during the occlusion. The perfusion pressure in these hearts was adjusted in the same way as with the action potential recording experiments above.
A K ATP opener shortened action potentials during coronary occlusion
During a 10 min coronary artery occlusion, the K ATP opener Ro 31-6930 caused a concentration-dependent shortening of action potentials recorded from the area at risk of ischaemia. Fig. 4 shows the time course of the effects of a low concentration of Ro 31-6930 (0.5 µM) on these left ventricular action potentials. This drug had no significant effect on either APD 50 or APD 80 prior to coronary occlusion, but it significantly shortened APD 80 below the corresponding control values at each time point during the period of occlusion, and APD 50 values at most time points studied (n = 13 hearts, 7-13 action potentials, P < 0.05). This effect of the K ATP opener became evident after only 1 min of coronary occlusion (Fig. 4) . Beyond 4 min of 254 Basic Values are means, with the S.E. of duration data indicated by error bars. NV = no value recorded, i.e. zero. For groups of Ro 31-6930-treated hearts (n = 7-10), *denotes a significant difference (P < 0.05) from the control value (i.e. with Ro 31-6930 at 0 µM). Hearts treated with glibenclamide (n = 9-10 per group): both the incidence and duration of VT in hearts treated with glibenclamide alone (indicated by 0 µM Ro 31-6930 in combination with 1 µM glibenclamide) were not significantly different from the control values of 0 % and 0 s, respectively. There were no significant differences in either the incidence or duration of VT between any of the drug-combination-treated groups.
coronary occlusion, Ro 31-6930 also shortened APD 80 values below the pre-occlusion values at each time point (P < 0.05). This contrasts markedly with the situation in the absence of the K ATP opener. Figure 5 shows the effects of a high concentration of Ro 31-6930 (5 µM), administered under similar conditions. During coronary occlusion, Ro 31-6930 at 5 µM markedly shortened both APD 50 and APD 80 at each time point, compared to the corresponding control values (Fig. 5a) , and in this case, the drug abolished the transient APD-lengthening that was seen in the control group. As at the lower concentration (0.5 µM), Ro 31-6930 at 5 µM also significantly shortened action potentials below the pre-occlusion value seen during coronary occlusion (n = 13, P < 0.05). However, in contrast to the effects of the low concentration, the high concentration (5 µM) of the K ATP opener caused significant APD-shortening even before the occlusion, by 50 and 62 %, for APD 50 and APD 80 , respectively (n = 13, P < 0.05). Again, none of these electrical effects of the K ATP opener were likely to have been complicated by its vasodilator action, since the coronary flow rates were adjusted to not be significantly different in control and drug-treated groups. Fig. 6 summarises these concentration-dependent effects of Ro 31-6930 in the two experimental phases. Significant shortening of APD prior to ischaemia only occurred with the K ATP opener at high concentration, but the shortening of APD during ischaemia occurred at both 0.5 and 5 µM. When APD 80 shortened to much below 10 ms, i.e. during coronary Values are means (n = 13 hearts, 7-13 action potentials), with error bars denoting S.E. In each heart, the left main coronary artery was occluded at time 0, indicated by vertical arrow. *denotes significant differences (P < 0.05) from control values at each time point, prior to and during coronary occlusion. occlusion in hearts treated with 5 µM Ro 31-6930, paroxysms of VT became evident in the action potential recordings. After 5 min of occlusion, it became impossible to measure APD due to continuous VT (Fig. 5b) . This pro-arrhythmic effect of Ro 31-6930 at 5 µM, and its association with a severely shortened APD 80 are shown in Figs. 3 and 6 .
Action potential shortening by the K ATP opener was glibenclamide-sensitive
The K ATP blocker glibenclamide abolished the effects on APD 50 and APD 80 , of both concentrations of the K ATP opener Ro 31-6930, not only before, but also during coronary artery occlusion. Fig. 7a shows that glibenclamide at the low concentration of 1 µM completely prevented the shortening of APD 80 that was caused by Ro 31-6930 at 0.5 µM during the period of coronary occlusion (compare this with Fig. 4 ). The complete reversal by 1 µM glibenclamide of Ro 31-6930-induced APD-shortening was evident even when using 5 µM Ro 31-6930 ( Fig. 7b compared with Fig. 5a ). This reversal by glibenclamide of the effects of Ro 31-6930 on APD during coronary occlusion, i.e. a restoration of the normal APD, is consistent with the prevention by glibenclamide of the proarrhythmic effects of the K ATP opener seen in Fig. 3 , and confirms the involvement of K ATP activation in both of these effects.
Discussion
We have provided evidence to suggest that K ATP channels do not open during the first 10 min of myocardial regional ischaemia in Langendorff-perfused rat hearts. In agreement with several previous studies on rat isolated hearts (26) (27) (28) 40 ), ischaemia did not shorten the action potential duration, thus raising the possibility that the K ATP channels had not opened early during the coronary artery occlusion. Our data obtained with pharmacologic K ATP modulation support this possibility, since the opening of K ATP channels was able to cause marked APD-shortening during ischaemia [clearly detectable despite the normal (26-28, 40) APD-lengthening seen in the absence of a drug], yet glibenclamide, which was able to completely abolish that effect of the K ATP opener (even after 10 min of ischaemia) had no significant effect on the APD during that time, when it was delivered alone, and at the same concentration.
We used as an index of K ATP activity, the sensitivity of the monophasic action potential (MAP) duration to pharmacologic K ATP modulation, not, importantly, the ischaemic APDchange per se. Direct measurement of I KATP (such as with voltage clamping of single channels) is unfeasible in the intact heart, and the latter model was used to study the electrical consequences of "true" myocardial ischaemia [as opposed to "simulated" ischaemia, which inevitably must be utilised when measuring single channel currents directly (37)]. The repolarisation time course of the MAP, such as that recorded using a suction electrode, accurately reproduces that of the action potential recorded with microelectrodes from the same region (14) , and the constancy of our suction electrode recordings over a 45 min experimental period demonstrates the reliability of the method in our model.
The time course of the ischaemia-induced APD changes, namely, marked and transient lengthening, closely followed the reported transmembrane APD changes in rat isolated hearts during 25 min of global low-flow ischaemia (26) . The cause of the early transient APD increase is unknown. Mechanical changes, a fall in either temperature or intracellular pH, and the release of catecholamines has each been suggested (7), as well as blockade of both the inward rectifier (I K1 ) (13, 35) and transient outward (I TO ) (33) K + currents. It should be noted that such marked APD-prolongation is largely species specific: in mammals larger than the rat, early ischaemic APD change is characterised mainly by prominent shortening. In the study of Henry et al. (13) , rat isolated ventricular myocytes were used, so coronary artery mechanical deflation was therefore absent, yet a similar transient APD-lengthening was demonstrated 256 Basic during simulated ischaemia. Moreover, it is important to note that a fall in temperature did not occur in the present study. Catecholamine release could only have been local (as opposed to systemic) in the present, in vitro, model, and local release is known to be negligible during the first 10-15 min of ischaemia (4). In the absence of the much larger, second phase accumulation of catecholamines which occurs in vivo after 15 min of ischaemia, catecholamine release would not have substantially influenced APD during ischaemia in the present experiments, which is consistent with the absence of heart rate increase during ischaemia. In contrast, acute blockade of I TO (a major repolarising current in the rat ventricle) is a more likely candidate for the APD-prolongation (33) , and such an ionic mechanism is consistent with a significant prolongation of the APD by 4-aminopyridine in this model (40) and could account for a suppression of phase 1 repolarisation during ischaemia (Fig.  1c) . Since the APD-lengthening during early ischaemia was abolished by the K ATP opener Ro 31-6930 and this effect was glibenclamide-sensitive, this suggests that any non-I KATPinduced changes that might tend to increase APD were unable to mask any concurrent effect of K ATP opening on APD.
In the present study, the K ATP opener Ro 31-6930 caused action potential shortening and VT during the 10 min period of coronary occlusion, each in a concentration-dependent manner. Ro 31-6930 is related to the benzopyran K ATP opener cromakalim, but has a non-chiral structure of much higher biological potency (8) . Its K ATP opening activity has previously been demonstrated in several experimental models (3, 10, 12) , including cardiac tissue, in which 3 µM Ro 31-6930 caused action potential shortening, which was reversed both by ATP (100 µM) and glibenclamide (0.3-3 µM) (3). It is noteworthy that we report a greater decrease in APD by 0.5 µM Ro 31-6930 during early ischaemia, than prior to ischaemia. It has been shown previously that an increase in intracellular [ADP] reduced the sensitivity of K ATP channels to block by ATP (17) . Therefore, it might be speculated that such a biochemical event (or other, e.g. an increased intracellular acidosis or accumulation of adenosine) might sensitise K ATP to an opening action of Ro 31-6930, possibly as a result of reduced inhibitory effect of ATP on the K ATP channel. The significant pro-arrhythmic effect of Ro 31-6930 during ischaemia is consistent with a proarrhythmic effect from cromakalim-induced K ATP activation seen in a previous study during a 10 min period of occlusion in rat working hearts (9) . The Ro 31-6930-induced VT that we observed even prior to ischaemia has also been seen by other workers with related drugs (6) . Other studies on intact hearts have revealed significant K ATP opener-induced arrhythmogenesis and a shortening of the QT interval (36) and refractory periods (1) during ischaemia. The implications of this potentially undesirable property for the therapeutic use of this group of drugs warrants further study.
The K ATP blocker glibenclamide, at the relatively low concentration of 1 µM, completely reversed the APD-shortening and pro-arrhythmic effects of the K ATP opener Ro 31-6930 seen during 10 min of coronary artery occlusion. This, as well as confirming that these effects of Ro 31-6930 were due to K ATP activation, suggested that if K ATP activation should occur in the absence of a K ATP opening drug, it would be detectable as APD-shortening which would be glibenclamide-sensitive. The main supporting evidence that the K ATP channels had not opened during the occlusion alone, therefore, was provided by using glibenclamide alone, since at the same concentration (1 µM) which abolished the APD-shortening effects of the K ATP opener, glibenclamide had no effect on the action potentials during the occlusion.
Previously reported electrical effects of glibenclamide during ischaemia or hypoxia have been variable. Moritani et al. (22) demonstrated a complete suppression of APD-shortening hearts, 7-15 action potentials, for each control and drug combinationtreated group). In each heart, the left main coronary artery was occluded at time zero, indicated on the time scales by the vertical arrows. Asterisks denote significant differences (P < 0.05) from control values at each time point, prior to and during coronary occlusion. during a 5 min coronary occlusion in dogs in vivo. Some attenuation by glibenclamide of APD-shortening during ischaemia (5, 30) , hypoxia (20, 29) and dinitrophenol-induced metabolic blockade (23) has also been reported. Glibenclamide had no effect until 45 min of hypoxia had occurred in the rabbit, however (29) , but some attenuation of the refractory period shortening occurred in a similar model (1) . In canine ventricular isolated tissues, glibenclamide also was unable to restore the loss of the action potential plateau induced by simulated ischaemia (19) .
The lack of effect of glibenclamide on the APD in the present study is consistent with a study by Wilde et al. (38) who have demonstrated that, in rat isolated hearts, extracellular K + accumulation (the earliest effect detected during ischaemia, and at least partly mediated by K + channels) also was insensitive to glibenclamide during early ischaemia.
Glibenclamide, although not entirely selective for K ATP channels, is nevertheless acknowledged as one of the best presently available K ATP blockers. However, it is acknowledged that, in some studies, doubts have been raised concerning the efficacy of glibenclamide to block K ATP channels during ischaemia or hypoxia. Venkatesh and colleagues have suggested that an accumulation of cytosolic ADP, such as occurs early during ischaemia (when [ADP] rises rapidly to the 100 µM range), might limit the ability of glibenclamide (even at 100 µM) to block cellular K + loss in guinea pig ventricular myocytes during metabolic blockade (32) . Use of the nonsulphonylurea 5-hydroxydecanoate (5-HD) might be considered in future studies, although it has been shown previously (22) that no additional K ATP blocking effect of 5-HD occurred during coronary occlusion in dogs, to that produced by pretreatment with glibenclamide. It is noteworthy that 5-HD has been reported to be selective for mitoK ATP (21) , and its use, therefore, may not be appropriate for investigating sarcolemmal K ATP channels. Nevertheless, a study of effects of 5-HD on the electrophysiological responses to Ro 31-6930 in this model might be considered. In the present study, we found that 10 µM glibenclamide produced quantitatively similar results to 1 µM, and owing to the complete antagonism of Ro 31-6930's effects with 1 µM and the reduced risk of actions additional to I KATP blockade [such as block of cardiac ventricular A-kinasedependent Cl -current with > 1 µM glibenclamide (31)], we chose to do the majority of experiments with 1 µM glibenclamide. The preservation of the K ATP modulating drugs' effects was an important factor to consider in our interpretation of the results, and in the present study, 1 µM glibenclamide was able to entirely block effects of Ro 31-6930 on both APD and VT, during coronary occlusion, as well as before it, indicating its suitability to block K ATP channels during ischaemia in the present model.
Limitations of the study
The following should be considered when interpreting our findings. Firstly, it is unknown to what depth of tissue MAPs are recorded, since these are injury currents flowing from an area of uninjured tissue surrounding depolarised cells beneath the electrode. Therefore, the MAPs recorded from the ischaemic zone during coronary ligation inevitably contained a component from the surrounding, normally perfused zone. Such a component should not seriously limit interpretation of the data, however, since it does not seem to have been large enough to prevent clear detection of APD-shortening in the ischaemic zone with low dose Ro 31-6930, despite this concentration having been shown to have no effect on the APD in normally perfused muscle (and presumably, therefore, on non-ischaemic tissue during regional ischaemia). Secondly, it is unclear why 1 µM glibenclamide caused a small degree of APD-shortening prior to ischaemia. The only expected effect on APD of blockade of any open K ATP channels prior to ischaemia would be to prolong, not shorten it, and so we cannot exclude the possibility that effects additional to K ATP blockade were operating, and that these might have had a similar effect on the APD during ischaemia. In comparison, however, the pronounced and 1 µM glibenclamide-sensitive APD-shortening effects of the K ATP opener seen during ischaemia lend support to our conclusion that K ATP had largely remained closed during ischaemia in the absence of drugs. Thirdly, the use of an in vitro preparation coupled with a relatively short period of ischaemia and relatively high perfusate [KCl] , whilst permitting action potential recording, is known to result in fewer and less severe episodes of VT than would be encountered in vivo with a longer ischaemic insult, and may be associated with a sub-physiological heart rate. Finally, the fact that, in a rat heart performing no external work, no APDshortening was observed during a 10 min period of ischaemia [and none would be expected even during 30 min in this model (26) ] does not preclude K ATP activation prior to this in hearts of other species, and in those performing external work, either in vitro or in vivo. The present results, therefore, may be both model-and species-dependent.
In summary, whilst caution must be exercised in interpreting a complex situation in a specific experimental model, our data suggest that cardiac K ATP channels did not open as a prominent feature during the first 10 min of myocardial regional ischaemia in the Langendorff-perfused rat heart.
